ISSN 1662-4009 (online)

ey0018.1-13 | Clinical/Translational | ESPEYB18

1.13. Anterior pituitary function in Rathke's cleft cysts versus nonfunctioning pituitary adenomas

M Fujii , A Nakagawa , O Tachibana , H Iizuka , D Koya

Endocr J. 2021 Apr 3. doi: 10.1507/endocrj.EJ21-0050. PMID: 33814485.Mizue Fujii and colleagues retrospectively evaluated the pituitary function in 67 and 111 adult patients with Rathke’s cleft cyst (RCC) and non-functioning pituitary adenoma (NFA), respectively. The study population represented consecutive patients encountered in their institute. They found that RCCs were smaller t...

ey0018.4-7 | Growth Hormone Therapy: Safety | ESPEYB18

4.7. Association of childhood growth hormone treatment with long-term cardiovascular morbidity

A Tidblad , M Bottai , H Kieler , K Albertsson-Wikland , L Savendahl

JAMA Pediatr. 2021;175(2):e205199. doi: 10.1001/jamapediatrics.2020.5199. PMID: 33346824This nationwide population-based study assessed the long-term risk of cardiovascular events in patients who had received rhGH therapy during childhood and adolescence. The study cohort comprised 3.408 subjects treated under the GHD, SGA or ISS indications, and 50 036 age-, sex-, and region-base...

ey0019.12-11 | Hyperlipidemia | ESPEYB19

12.11. Identification and evaluation of a lipid-lowering small compound in preclinical models and in a Phase I trial

H. Wang J, Zhao J, Yan C, Xi C, Wu C, Zhao J, Li F, Ding Y, Zhang R, Qi S, Li X, Liu C, Hou W, Chen H, Wang Y, Wu D, Chen K, Jiang H, Huang H, Liu

Cell Metabolism 2022;34(5):667-80.e6. doi: 10.1016/j.cmet.2022.03.006Brief Summary: In preclinical models and a phase 1 trial, a powerful new lipid small molecule was shown to act through a mechanism distinct from those of known hypolipidemic agents. Targeting HNF-1α may be a new therapeutic strategy.Comment: Familial hypercholesterolemia (FH) is the most common...

ey0019.12-13 | Hyperlipidemia | ESPEYB19

12.13. Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia

Y Fukami H, Morinaga J, Nakagami H, Hayashi H, Okadome Y, Matsunaga E, Kadomatsu T, Horiguchi H, Sato M, Sugizaki T, Kuwabara T, Miyata K, Mukoyama M, Morishita R, Oike

Reports Medicine 2021;2(11):100446. doi: 10.1016/j.xcrm.2021.100446Brief Summary: This mouse study validated a novel, safe treatment with ANGPTL3 peptide vaccine. It was effective to improve obesity-induced dyslipidemia and fatty liver in mice, and also improved dyslipidemia and atherosclerosis in a mouse model of familial hypercholesterolemia, with no reported toxicity.<p class="abste...

ey0017.12-3 | Type 2 Diabetes | ESPEYB17

12.3. NIPA2 regulates osteoblast function by modulating mitophagy in type 2 diabetes osteoporosis

W Zhao , W Zhang , H Ma , M Yang

To read the full abstract: Sci Rep. 2020;10(1):3078. doi: 10.1038/s41598-020-59743-4Short summary: This study describes a specific mechanism of reduced bone formation secondary to hyperglycaemia. In hyperglycaemic states, advanced glycation end products (AGEs) downregulate the highly selective magnesium transporter expression of NIPA2 in osteoblasts. This results in ma...

ey0017.15-1 | (1) | ESPEYB17

15.1. Preconception diabetes mellitus and adverse pregnancy outcomes in over 6.4 million women: A population-based cohort study in China

Y Wei , Q Xu , H Yang , Y Yang , L Wang , H Chen , C Anderson , X Liu , G Song , Q Li , Q Wang , H Shen , Y Zhang , D Yan , Z Peng , Y He , Y Wang , Y Zhang , H Zhang , X Ma

To read the full abstract: PLoS Med. 2019 Oct 1;16(10):e1002926. doi: 10.1371/journal.pmed.1002926.The authors analysed a huge dataset from the Chinese national programme of preconception health checks, which include measurements of fasting plasma glucose. Overall, 13.15% (n =847,737) had impaired fasting glucose and 1.18% (n =76,297 women) had diabetes, of whom only...

ey0016.2-12 | Maternal Obesity and Long-term Infant Consequences | ESPEYB16

2.12. Maternal obesity impairs skeletal development in adult offspring

JR Chen , OP Lazarenko , H Zhao , AW Alund , K Shankar

To read the full abstract: J Endocrinol. 2018 Jul 26.This study, using a mouse model, investigated the effects of high fat diet-induced maternal obesity on both fetal and adult offspring skeletal development.Maternal nutrition appears to influence epigenetic alterations in the offspring and to program gene expression in key metabolic pathways, such as fatty acids a...

ey0016.15-17 | (1) | ESPEYB16

15.17. Spray dried smectite clay particles as a novel treatment against obesity

TJ Dening , P Joyce , M Kovalainen , H Gustafsson , CA Prestidge

To read the full abstract: Pharm Res. 2018 Dec 5;36(1):21.Smectite purified from bentonite clay, and laponite SD-LAP, a synthetic Smectite were fed to rodents on a high-fat diet. Over a two-week period both the engineered clay and orlistat had weight loss effects.The unanticipated discovery that clay has a unique ability to “soak up” fat droplets in the g...

ey0015.7-1 | New concept: Epigenetic control of puberty | ESPEYB15

7.1 Trithorax dependent changes in chromatin landscape at enhancer and promoter regions drive female puberty

CA Toro , H Wright , CF Aylwin , SR Ojeda , A Lomniczi

To read the full abstract: Nat Commun. 2018 Jan 4;9(1):57The hypothalamic-pituitary-gonadal axis controls the onset of puberty and the acquisition of the reproductive function. A subset of neurons in the anterior hypothalamus secretes gonadotropin-releasing hormone (GnRH) which, through its pattern of release controls all aspects of reproduction throughout life. The secretory activity of GnR...

ey0021.2-8 | Genotype-Phenotype and SRS | ESPEYB21

2.8. Pathogenic sequence variant and microdeletion affecting HMGA2 in Silver- Russell syndrome: case reports and literature review

K Yamoto , H Saitsu , Y Ohkubo , M Kagami , T Ogata

Brief Summary: Two Japanese children with Silver Russell Syndrome (SRS) are reported, one with a de novo pathogenic frameshift sequence variant (Case 1) and the other with a 3.4 MB de novo microdeletion (Case 2) in HMGA2 (High Mobility Group AT-hook 2; OMIM *600,698). Both genetic findings meet the criteria established by the ACMG/AMP1. Case 1 had 5 of 6 (no body asymmetry) and Case 2 had 4 of 6 (no prominent forehead or body asymmetry) of...